ArticleGland surgery2026
Evaluating microwave ablation for treating large benign thyroid nodules.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Large benign thyroid nodules (BTNs) (≥4 cm) are often situated in close proximity to critical tissues, posing unique challenges for treatment. Microwave ablation (MWA), known for its ability to generate consistently higher intratumoral temperatures, has emerged as a promising non-surgical alternative. This study aimed to assess the efficacy and safety of MWA when treating patients harboring large BTNs, and explore the strategy for protecting against recurrent laryngeal nerve (RLN) injury. Methods: A retrospective analysis of 205 patients with BTNs who underwent MWA was conducted. Clinical and ultrasound (US) analyses were performed at 1, 6, and 12 months post-ablation. The volume reduction rate (VRR), associated factors, and complications were analyzed. Results: For patients in this cohort, the respective mean nodule diameter and volume were 46.56±7.66 mm and 22.91±15.23 mL. Of the 205 nodules, 59 were solid, and 146 were predominantly solid. At 12 months, the mean VRR was 82.54%, with a technical efficacy rate of 93.66%. Multivariate analysis revealed that VRR was significantly associated with nodule composition at 6 months but not at 12 months. Eighteen cases necessitated repeat ablation owing to difficulties in maintaining an effective isolating fluid width, with this issue being attributable to high levels of tension between the thyroid nodule and the tracheoesophageal groove. One patient developed transient hoarseness, that was fully resolved within 1 month after ablation. Conclusions: MWA can be safely and effectively used to treat large BTNs. Secondary ablation is a crucial strategy for mitigating RLN injury when isolating fluid is insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.